Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Could the specific glycosylation signatures associated with tumour cells be harnessed for immunotherapy purposes? In this Opinion, the authors propose that the tumour glyco-code may represent a novel immune checkpoint that could be targeted in the clinic.
Normalization of the tumour vasculature can improve immune effector cell infiltration, leading to immunotherapy potentiation. In this Opinion article, Huanget al. propose that reciprocal regulation between tumour vascular normalization and immune reprogramming forms a positive feedback loop that can induce durable antitumour immunity within the tumour microenvironment.
